Yuliya Katlinskaya
Senior Principal Scientist Amgen Inc.
Seminars
Tuesday 16th September 2025
Biomarker Insights & Resistance Mechanisms in KRAS G12C-Mutated mCRC: Findings from the Phase 3 CodeBreaK 300 Study
3:15 pm
- Identify key baseline co-alterations and their impact on treatment response
- Characterize emergent alterations at progression
- Inform future combination strategies
